Sorafenib plus transarterial chemoembolization vs sorafenib alone for patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis

doi:10.4254/wjh.v16.i1.91

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1948)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-4) series.

Item

Count

PDF

WORD

HTML

753

Figures (1-4)

124

Tables (1-4)

131

Sum=1055

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

107

Download

317

Sum=424

Publishing Process of This Article

Item

Count

Browse

Download

315

Sum=414

Jan 27, 2024 (publication date) through Jul 27, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Hepatol. Jan 27, 2024; 16(1): 91-102
Published online Jan 27, 2024. doi: 10.4254/wjh.v16.i1.91

Full Size Figure Download Figure

Figure 2 Meta-analysis of efficacy outcomes in patients with advanced hepatocellular carcinoma receiving sorafenib plus transarterial chemoembolization or sorafenib alone. A: Forest plot of overall survival; B: Forest plot of progression free survival; C: Forest of time to progression; D: Forest plot of disease control rate. The pooled results were calculated by using a random-effects model. 95%CI: 95% confidence interval; TACE: Transarterial chemoembolization.

Citation: Yang HJ, Ye B, Liao JX, Lei L, Chen K. Sorafenib plus transarterial chemoembolization vs sorafenib alone for patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis. World J Hepatol 2024; 16(1): 91-102
URL: https://www.wjgnet.com/1948-5182/full/v16/i1/91.htm
DOI: https://dx.doi.org/10.4254/wjh.v16.i1.91